Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Australian Clinical Labs Limited (ACL.AX)
Clayton, VIC, AU
Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening. Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services. ACL also performs infectious molecular testing, cardiac diagnostic assessments, functional pathology, veterinary pathology, and commercial drug and alcohol screening. These essential services are supplied to both private and public hospitals throughout the nation. The company was founded in 2020 and maintains its primary operational base in Clayton, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.27% | +2.53% | +7.41% | -10.18% | -30.48% | -26.18% | -28.77% | -37.54% | -43.14% | -40.64% | -40.64% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 6 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+7.5% Q4'25: +8.3% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+41.7% ★ Q4'25: +16.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+6.6% Q4'25: +16.4% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+9.2% Q4'25: +5.4% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%+10.5% ★ Q4'25: +8.1% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%-4.6% ★ Q4'25: -3.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×3.57× Q4'25: 1.31× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 8 Rev. Ana. 6 EPS Ana. |
Jun 2027 8 Rev. Ana. 7 EPS Ana. |
Jun 2028 7 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
641.31M
est: 668.41M (-4.1%)
|
989.30M
est: 988.20M (+0.1%)
|
692.10M
est: 712.57M (-2.9%)
|
689.73M
est: 687.28M (+0.4%)
|
741.27M
est: 745.50M (-0.6%)
|
737.66M
732.14M – 741.05M
-1.1% YoY
|
762.67M
751.94M – 773.49M
+3.4% YoY
|
795.04M
793.58M – 796.51M
+4.2% YoY
|
| EBITDA |
196.67M
est: 174.64M (+12.6%)
|
372.75M
est: 258.19M (+44.4%)
|
184.93M
est: 186.18M (-0.7%)
|
169.65M
est: 179.57M (-5.5%)
|
81.36M
est: 194.78M (-58.2%)
|
192.73M
191.29M – 193.62M
-1.1% YoY
|
199.27M
196.46M – 202.09M
+3.4% YoY
|
207.72M
207.34M – 208.11M
+4.2% YoY
|
| EBIT |
108.62M
est: 90.94M (+19.4%)
|
266.65M
est: 134.44M (+98.3%)
|
62.18M
est: 96.95M (-35.9%)
|
41.22M
est: 93.50M (-55.9%)
|
68.00M
est: 101.43M (-33.0%)
|
100.36M
99.61M – 100.82M
-1.1% YoY
|
103.76M
102.30M – 105.23M
+3.4% YoY
|
108.17M
107.97M – 108.37M
+4.2% YoY
|
| Net Income |
60.37M
est: 85.23M (-29.2%)
|
178.24M
est: 185.32M (-3.8%)
|
35.90M
est: 39.34M (-8.7%)
|
23.93M
est: 28.65M (-16.5%)
|
32.43M
est: 32.43M (+0.0%)
|
26.61M
20.31M – 31.50M
-18.0% YoY
|
34.27M
28.34M – 38.40M
+28.8% YoY
|
38.79M
35.15M – 42.55M
+13.2% YoY
|
| SGA |
249.69M
est: 168.82M (+47.9%)
|
314.00M
est: 249.59M (+25.8%)
|
297.39M
est: 179.97M (+65.2%)
|
87.19M
est: 173.59M (-49.8%)
|
—
est: 188.29M (-100.0%)
|
186.31M
184.92M – 187.17M
-1.1% YoY
|
192.63M
189.92M – 195.36M
+3.4% YoY
|
200.80M
200.43M – 201.17M
+4.2% YoY
|
| EPS |
0.40
est: 0.45 (-10.7%)
|
0.89
est: 0.97 (-8.6%)
|
0.18
est: 0.21 (-13.4%)
|
0.12
est: 0.15 (-20.3%)
|
0.17
est: 0.18 (-4.6%)
|
0.15
0.11 – 0.17
-15.5% YoY
|
0.17
0.15 – 0.20
+15.9% YoY
|
0.20
0.18 – 0.22
+12.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-25 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares S&P/ASX Small Ordinaries ETF ISO.AX | 0.15% | 128.2K | 0.55% |
| 2 | iShares S&P/ASX Dividend Opportunities ESG Screened ETF IHD.AX | 0.09% | 236.7K | 0.23% |
| 3 | BetaShares - FTSE RAFI Australia 200 ETF QOZ.AX | 0.06% | 518.0K | 0.40% |
| 4 | State Street SPDR S&P International Small Cap ETF GWX | 0.05% | 425.7K | 0.40% |
| 5 | WisdomTree International SmallCap Dividend Fund DLS | 0.05% | 492.1K | 0.58% |
| 6 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.04% | 187.8K | 0.48% |
| 7 | WisdomTree International High Dividend Fund DTH | 0.02% | 105.3K | 0.58% |
| 8 | Vanguard Australian Shares Index ETF VAS.AX | 0.01% | 2.44M | 0.07% |
| 9 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 560.2K | 0.06% |
| 10 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 31.7K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Melinda McGrath | Chief Executive Officer, MD & Executive Director | 3M | female |
| Matthew Cordingley | Chief Financial Officer | 754.7K | male |
| Darren McKee | Chief Executive Officer of Victoria | 37.3K | male |
| Eleanor Padman FCIS | Company Secretary | — | female |
| Joe Geran | National Marketing Director | — | male |
| Sean Jackson | Chief Information Officer | — | male |
| Anthony Friedli | Chief Operating Officer | — | male |
| Shae Seymour | Chief Risk Officer & Chief Executive Officer of WA/SA/NT | — | female |
| Associate Tony Landgren | National Medical Director & Chief Pathologist | — | — |
| Chris Brownlow | Chief Executive Officer of New South Wales & Australian Capital Territory | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACL.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
